The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed
from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on
the promising clinical efficacy of the dose escalation study, this study is designed to
evaluatee the clinical efficacy and safety of 160mg lazertinib.